PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Summary

This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab, INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy. Additionally, the study will investigate that triple checkpoint blockade of PD-1, TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses.

Timeline

Start

2024-08-30

Primary completion

2026-06-30

Completion

2028-01-31

Drugs

Indications